Closed Loop Medicine Appoints Paul Johnson as Non-Executive Director
May 22 2024 - 4:43AM
Business Wire
- Appointment of digital healthcare leader to Board to support
the Company as it enters next phase of commercial development
- Co-founder and former CEO of Lemonaid Health, a leading
innovator in telemedicine and prescription drug delivery, acquired
by 23andMe in 2021
Closed Loop Medicine Ltd., a leading TechBio company developing
combination prescription drug plus software therapy products that
deliver personalized dose optimization, today announced the
appointment of Paul Johnson as an Independent Non-Executive
Director. A notable entrepreneur in the industry, Paul brings
unique and extensive experience in the development and scaling of
digital healthcare and e-commerce platforms to the Board of
Directors. He joins at a pivotal stage in the Company’s development
as it prepares for breakthrough milestones in the progression and
commercialization of its product pipeline.
Paul is an established leader within the digital healthcare
industry, having co-founded Lemonaid Health, one of the first
national direct-to-consumer telehealth apps in the US, and led the
Company as CEO through to its acquisition by consumer genetics and
research company, 23andMe, for $400 million in 2021. Paul then
became VP and General Manager, and later COO, of the wider 23andMe
consumer business, which includes Lemonaid Health, providing its
innovative telemedicine platform to advance 23andMe’s vision of
individualized primary care. Prior to moving to the US, Paul was
Head of Online at McKesson UK, where he was responsible for the
online P&L and all digital activity for the Group’s brands,
including Lloyds Pharmacy. In 2010, as UK Managing Director, he
launched the Zooplus business in the UK, Europe’s leading online
pet shop. Paul is an advisor to several technology-first companies
and leading venture funds, he is a CEO coach and an active angel
investor.
Harnessing his specialist experience and expertise in digital
platforms and direct-to-consumer medical services, Paul joins
Closed Loop Medicine’s Board to support the leadership team in
driving forward the commercialization strategy for its portfolio of
integrated precision care solutions. His appointment is the third
leadership-level appointment within the past year and follows
several recent commercial milestones, including publication of
breakthrough clinical trial data validating use of the Company’s
proprietary technology to identify personalized dose regimens in
the treatment of hypertension, leading to improved blood pressure
control and exceptionally high medication adherence1. The findings
will be applied as the Company further extends its pipeline of
combination products across other therapeutic areas including in
obesity to provide a patient-centered dose optimization tool for
robust differentiation in the GLP-1 market.
Paul Johnson, Non-executive Director of Closed Loop Medicine,
commented: “Closed Loop Medicine's approach to delivering
personalized and integrated healthcare aligns with my commitment to
building digital product experiences that treat patients as
individuals, rather than an average of a population set. Throughout
my career, I've championed digital solutions to provide accessible
healthcare for all. With its proprietary dose optimization
platform, the Company is going a step further to improve outcomes
at the individual level.” He added: “It is clear I am
joining Closed Loop Medicine at a very transformative stage in its
development, and I am very much looking forward to supporting the
Company in bringing forward the promise of precision care, as it
realizes the potential of its product pipeline.”
Dr. Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop
Medicine, said: “As we stand on the brink of realizing our vast
prospects within the industry, Paul's strategic insights and proven
track record will be instrumental to steering the Company to
continued growth and success. His notable achievements and deep
expertise in navigating the evolving telemedicine and digital
health landscape, particularly through his work at Lemonaid Health
and 23andMe, will undoubtedly play a focal role in bolstering the
Company’s strategic growth and commercialization of our disruptive
platforms.”
- Collier DJ et al. 2024.
https://www.ahajournals.org/doi/10.1161/JAHA.123.030749
To learn more about Closed Loop Medicine, visit:
www.closedloopmedicine.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522655375/en/
Media: Lily Jeffery (Zyme Communications) Email:
lily.jeffery@zymecommunications.com